Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 20/20 | 0.57 |
| ▸ | WNT1 | P04628 | 14/20 | 0.57 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | CLK3 | P49761 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706556 | 0.86 | PIK3C3 (0.53) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19736130 | 0.82 | GSK3B (0.45) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL19699553 | 0.76 | DYRK1A (0.57) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19699521 | 0.74 | DYRK1A (0.48) | GSK3BDYRK1AWNT1 | |
| SCHEMBL24932350 | 0.74 | EGFR (0.61) | GSK3B | |
| SCHEMBL19699524 | 0.73 | ADORA3 (0.50) | GSK3BDYRK1AWNT1 | |
| SCHEMBL30005216 | 0.73 | GSK3B (1.00) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19515249 | 0.73 | GSK3B (1.00) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19516003 | 0.72 | GSK3B (0.98) | GSK3BDYRK1AWNT1 | |
| SCHEMBL15627415 | 0.72 | TYK2 (0.52) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 2322/4885DYRK1A 3048/4885WNT1 3338/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 2340/4885DYRK1A 2959/4885WNT1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.